Literature DB >> 15795049

Mitochondrial aging and dysfunction in Alzheimer's disease.

Patrick G Sullivan1, Maile R Brown.   

Abstract

Disruptions in energy metabolism have been suggested to be a prominent feature, perhaps even a fundamental component, of Alzheimer's disease (AD). These abnormalities in cerebral metabolism precede the onset of neurological dysfunction as well as gross neuropathology of AD. These changes may stem from inhibition of mitochondrial enzymes including pyruvate dehydrogenase, cytochrome c oxidase, and alpha-ketoglutarate dehydrogenase. Several lines of evidence also suggest a role for oxidative stress in the neuropathology associated with the disease state. Because mitochondria are the major site of free radical production in cells, they are also a primary target for oxidative damage and subsequent dysfunction. This link between mitochondrial dysfunction and the pathophysiology of AD is supported by several lines of evidence.

Entities:  

Mesh:

Year:  2005        PMID: 15795049     DOI: 10.1016/j.pnpbp.2004.12.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  30 in total

1.  Cytochrome c oxidase subunit IV is essential for assembly and respiratory function of the enzyme complex.

Authors:  Youfen Li; Jeong-Soon Park; Jian-Hong Deng; Yidong Bai
Journal:  J Bioenerg Biomembr       Date:  2006-12       Impact factor: 2.945

2.  Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.

Authors:  Jens Brodbeck; Maureen E Balestra; Ann M Saunders; Allen D Roses; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

Review 3.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

4.  Low-level laser therapy for beta amyloid toxicity in rat hippocampus.

Authors:  Yujiao Lu; Ruimin Wang; Yan Dong; Donovan Tucker; Ningjun Zhao; Md Ejaz Ahmed; Ling Zhu; Timon Cheng-Yi Liu; Robert M Cohen; Quanguang Zhang
Journal:  Neurobiol Aging       Date:  2016-10-11       Impact factor: 4.673

5.  A Mild Traumatic Brain Injury in Mice Produces Lasting Deficits in Brain Metabolism.

Authors:  Danielle N Lyons; Hemendra Vekaria; Teresa Macheda; Vikas Bakshi; David K Powell; Brian T Gold; Ai-Ling Lin; Patrick G Sullivan; Adam D Bachstetter
Journal:  J Neurotrauma       Date:  2018-07-02       Impact factor: 5.269

6.  An Exploratory Analysis of Potential New Biomarkers of Cognitive Function.

Authors:  Matthew J Peterson; Sheena Geoghegan; Larry W Lawhorne
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-02-15       Impact factor: 6.053

Review 7.  Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far?

Authors:  Raymond Chuen-Chung Chang; Kwok-Fai So
Journal:  Cell Mol Neurobiol       Date:  2007-08-21       Impact factor: 5.046

Review 8.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 9.  Mouse models of mitochondrial complex I dysfunction.

Authors:  Michael H Irwin; Kodeeswaran Parameshwaran; Carl A Pinkert
Journal:  Int J Biochem Cell Biol       Date:  2012-08-10       Impact factor: 5.085

10.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.